Diabetic dyslipidemia: a practical guide to therapy.
Low-density lipoprotein (LDL) should be the primary target of lipid-lowering therapy for patients with diabetes. Because of their robust reduction of LDL, statins are considered the agents of choice for these patients. Triglyceride (TG) and high-density lipoprotein (HDL) levels are also important targets. Combination therapy with fibrates or niacin is common due to concurrent high TG and low HDL levels in these patients. Data supporting an LDL goal of <70 mg/dL for patients with diabetes are limited and contradictory at this time.
Feik School of Pharmacy, University of the Incarnate Word San Antonio, TX USA. jmtovar@uiwtx.edu
John M
JM
Tovar
Oralia V
OV
Bazaldua
Alexandra
A
Loffredo
D002995:Clofibric Acid / Q000627:therapeutic use; D003327:Coronary Disease / Q000517:prevention & control; D048909:Diabetes Complications / Q000150:complications*; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D009525:Niacin / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011322:Primary Prevention; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D014280:Triglycerides; D009525:Niacin; D002995:Clofibric Acid